Research Roundup

Debbie Rigby takes a look at the latest research news Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease In this large double-blind event-driven trial, ticagrelor (90 mg twice daily) was not shown to be superior to clopidogrel (75 mg once daily) for the reduction of cardiovascular events in patients with symptomatic peripheral artery disease. Major

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous Facing the consequences
Next Pharmacists as good as doctors at prescribing: Cochrane Review